Jazz Pharmaceuticals: Pipeline Setback While Business Transition Continues

Jazz announced that suvecaltamide failed to meet the primary endpoint in the phase 2b trial, but the company is blaming the placebo response: The oxybate franchise is doing well despite the availability of generic Xyrem and the recent launch of Lumryz Jazz Pharmaceuticals earnings reports Jazz Pharmaceuticals earnings reports deliormanli Suvecaltamide fails in the phase 2b trial in patients with essential tremor While not statistically significant, numeric improvements were observed on the primary endpoint ...